24h
Actual
Mínimo
1340
Máximo
1342.5
Recomendaciones | Neutral |
---|---|
Estimación a 12 meses | +23.9 upside |
Próximas Ganancias | 5 feb 2025 |
---|---|
Fecha Próximo Dividendo | 9 ene 2025 |
Próxima Fecha de Ex Dividendo | 20 feb 2025 |
By Acuity
45%
55%
147 / 392 Clasificación en Healthcare
El rendimiento pasado no es un indicador fiable de resultados futuros.
15 nov 2024, 10:28 UTC
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
DJ
Leer
30 oct 2024, 11:44 UTC
GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness -- Update
DJ
Leer
30 oct 2024, 07:50 UTC
GSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine Demand
DJ
Leer
29 oct 2024, 13:39 UTC
GSK Buys Lupus Treatment For Up To $850 Million From Chimagen Biosciences
DJ
Leer
15 nov 2024, 13:08 UTC
Trump's RFK Pick Weighs on Vaccine Makers -- WSJ
DJ
Leer
15 nov 2024, 10:34 UTC
Vaccine Sector Sell-Off Looks Overdone -- Market Talk
DJ
Leer
15 nov 2024, 10:29 UTC
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
DJ
Leer
7 nov 2024, 11:53 UTC
Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com
DJ
Leer
7 nov 2024, 11:31 UTC
Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com
DJ
Leer
31 oct 2024, 19:48 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update
DJ
Leer
30 oct 2024, 15:04 UTC
GSK's 3Q Results Are a Mixed Bag -- Market Talk
DJ
Leer
30 oct 2024, 08:22 UTC
GSK's Vaccine Weakness Is a Major Concern -- Market Talk
DJ
Leer
30 oct 2024, 07:18 UTC
GSK Reiterates Guidance As HIV And Cancer Drug Demand Offset Vaccine Weakness -- MarketWatch
DJ
Leer
30 oct 2024, 07:04 UTC
GSK PLC Expects to deliver Around Middle of Existing Annual Guidance Ranges
DJ
Leer
30 oct 2024, 07:03 UTC
GSK PLC 3Q EPS 1.4p
DJ
Leer
30 oct 2024, 07:02 UTC
GSK PLC Had Seen 2024 Sales Growth of 7% to 9%
DJ
Leer
30 oct 2024, 07:02 UTC
GSK PLC Issues Dividend of 15p
DJ
Leer
30 oct 2024, 07:01 UTC
GSK PLC Had Seen 2024 Core Earnings Per Share Growth of 10% to 12%
DJ
Leer
30 oct 2024, 07:01 UTC
GSK PLC Had Seen 2024 Core Operating Pft Growth Between 11% and 13%
DJ
Leer
30 oct 2024, 07:01 UTC
GSK PLC Backs 2024 View
DJ
Leer
30 oct 2024, 07:00 UTC
Analysts Saw GSK PLC 3Q Net Pft GBP1.78B
DJ
Leer
30 oct 2024, 07:00 UTC
Analysts Saw GSK PLC 3Q Turnover GBP8.00B
DJ
Leer
30 oct 2024, 07:00 UTC
GSK PLC 3Q Loss/Shr 1.4p
DJ
Leer
30 oct 2024, 07:00 UTC
GSK PLC 3Q Turnover GBP8.01B
DJ
Leer
30 oct 2024, 07:00 UTC
GSK PLC 3Q Adj EPS 49.7p
DJ
Leer
30 oct 2024, 07:00 UTC
GSK PLC 3Q Pre-items, Pretax Pft GBP2.65B
DJ
Leer
30 oct 2024, 07:00 UTC
GSK PLC 3Q Pretax Pft GBP64M
DJ
Leer
30 oct 2024, 07:00 UTC
GSK PLC 3Q Oper Pft GBP189M
DJ
Leer
30 oct 2024, 07:00 UTC
GSK PLC 3Q Net Loss GBP58M
DJ
Leer
29 oct 2024, 13:24 UTC
GSK Buys Lupus Treatment For Up To $850 Mln From Chimagen Biosciences
DJ
Leer
By TipRanks
Estimación a 12 meses
Media 1,662.73 GBX 23.9%
Máximo 2,610 GBX
Mínimo 1,350 GBX
De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para GlaxoSmithKline PLC Dist en los últimos 3 meses.
By TipRanks
Neutral
13 ratings
4
Comprar
7
Mantener
2
Vender
De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para GlaxoSmithKline PLC Dist en los últimos 3 meses.
By Acuity
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
$